Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra, TLK199 Tablets)in Combination With Lenalidomide (Revlimid)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS).

Trial Profile

Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra, TLK199 Tablets)in Combination With Lenalidomide (Revlimid)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS).

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2013

At a glance

  • Drugs Ezatiostat (Primary) ; Lenalidomide
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 15 May 2012 Status changed from active, no longer recruiting to completed.
    • 15 May 2012 Results published in the Journal of Hematology and Oncology.
    • 13 Dec 2011 Preliminary results were reported in a Telik media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top